In the past week, CYTK stock has gone up by 5.80%, with a monthly gain of 13.38% and a quarterly plunge of -27.98%. The volatility ratio for the week is 4.15%, and the volatility levels for the last 30 days are 4.81% for Cytokinetics Inc The simple moving average for the last 20 days is 5.50% for CYTK’s stock, with a simple moving average of 48.71% for the last 200 days.
Is It Worth Investing in Cytokinetics Inc (NASDAQ: CYTK) Right Now?
Moreover, the 36-month beta value for CYTK is 0.67. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CYTK is 99.41M and currently, short sellers hold a 13.31% of that float. On April 12, 2024, CYTK’s average trading volume was 2.67M shares.
CYTK) stock’s latest price update
Cytokinetics Inc (NASDAQ: CYTK) has experienced a decline in its stock price by -1.57 compared to its previous closing price of 74.36. However, the company has seen a gain of 5.80% in its stock price over the last five trading days. Market Watch reported 2024-04-10 that A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.
Analysts’ Opinion of CYTK
Many brokerage firms have already submitted their reports for CYTK stocks, with UBS repeating the rating for CYTK by listing it as a “Neutral.” The predicted price for CYTK in the upcoming period, according to UBS is $92 based on the research report published on January 24, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CYTK reach a price target of $90, previously predicting the price at $60. The rating they have provided for CYTK stocks is “Equal-Weight” according to the report published on January 05th, 2024.
Goldman gave a rating of “Buy” to CYTK, setting the target price at $50 in the report published on November 09th of the previous year.
CYTK Trading at 0.62% from the 50-Day Moving Average
After a stumble in the market that brought CYTK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.61% of loss for the given period.
Volatility was left at 4.81%, however, over the last 30 days, the volatility rate increased by 4.15%, as shares surge +13.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.04% lower at present.
During the last 5 trading sessions, CYTK rose by +5.80%, which changed the moving average for the period of 200-days by +122.19% in comparison to the 20-day moving average, which settled at $69.80. In addition, Cytokinetics Inc saw -12.34% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CYTK starting from Malik Fady Ibraham, who sale 32,605 shares at the price of $74.31 back on Apr 09 ’24. After this action, Malik Fady Ibraham now owns 138,567 shares of Cytokinetics Inc, valued at $2,422,918 using the latest closing price.
Malik Fady Ibraham, the EVP Research & Development of Cytokinetics Inc, sale 32,604 shares at $67.56 during a trade that took place back on Mar 05 ’24, which means that Malik Fady Ibraham is holding 138,973 shares at $2,202,606 based on the most recent closing price.
Stock Fundamentals for CYTK
Current profitability levels for the company are sitting at:
- -65.9 for the present operating margin
- -32.4 for the gross margin
The net margin for Cytokinetics Inc stands at -69.64. The total capital return value is set at -0.69.
Based on Cytokinetics Inc (CYTK), the company’s capital structure generated 2.55 points at debt to capital in total, while cash flow to debt ratio is standing at -0.65. The debt to equity ratio resting at -1.64. The interest coverage ratio of the stock is -8.6.
Currently, EBITDA for the company is -484.31 million with net debt to EBITDA at -1.37. When we switch over and look at the enterprise to sales, we see a ratio of 1086.5. The receivables turnover for the company is 5.87for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.12.
Conclusion
To wrap up, the performance of Cytokinetics Inc (CYTK) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
